In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...
In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.
The findings suggest that the HER2DX assay could help clinicians decide on the appropriate use of chemotherapy in older patients, study researchers wrote.
News-Medical.Net on MSN
Global report reveals a decade of uneven progress in advanced breast cancer care
The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025 - a landmark global ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.
Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025.
When a woman feels a lump or a young mother notices an odd change in her breast, alarm sets in, not just from the possibility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback